We are pleased to announce that Vector Bioscience Cambridge is now an official member of the BioIndustry Association (BIA), the UK’s leading trade association for innovative life sciences and biotech companies.
Joining the BIA marks an important step for us as we continue to scale our platform and engage more broadly with the biotech and pharmaceutical community. The BIA plays a key role in shaping the UK life sciences ecosystem through policy engagement, networking opportunities, and support for innovation across the sector. For an early-stage company like Vector, access to a strong network and sector-wide insight is essential as we move from preclinical development to strategic partnerships and clinical readiness.
As part of our membership, the BIA invited our CEO and Co-Founder, Lluna Gallego, to share the journey of Vector Bioscience Cambridge and our ambitions for the future. In their blog post, Lluna outlines the origins of our ML-enabled nanoshuttle platform, our progress to date, and the priorities we are focusing on to bring our drug delivery technology closer to clinical translation.
“Our biggest achievement has been validating the potential of our MOF-based platform to solve some of drug delivery’s hardest problems — and doing so in a way that’s already attracted industry attention.” – Lluna Gallego
The interview also highlights the importance of building a scalable, GMP-aligned manufacturing process and the value of connecting with partners across the sector. From strengthening our preclinical data package to securing our first pharma collaboration, Vector is focused on delivering new solutions for more effective therapeutic delivery.
We invite you to read the full interview with Lluna on the BIA website here: 👉 Exploring the journey of Vector Bioscience Cambridge – BIA blog
Why BIA membership matters to us
Being part of the BIA connects us to a broader community of peers, partners, and policy-makers. It gives us access to relevant events, updates on regulatory and industry trends, and a platform to raise awareness of our work. We are especially looking forward to building relationships that support our mission to improve drug delivery for patients through data-driven, targeted, and more effective therapeutics.
We’re proud to join the BIA and look forward to contributing to and learning from the UK life sciences community.